Search clinical trials for: Elinzanetant (BAY3427080)

Total 21 results

Bayer

Completed

Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body

Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Germany
Bayer

Completed

A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally

Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

United States
Bayer

Completed

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

Hot Flashes | Healthy Volunteers | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

United States
Bayer

Completed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

Hot Flashes | Vasomotor Symptoms Associated With Menopause

United States, Switzerland, Canada, Poland, Italy, Germany, Portugal, Norway, Slovakia, Czechia
Bayer

Completed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-1)

Hot Flashes | Vasomotor Symptoms Associated With Menopause

United States, Netherlands, Hungary, Italy, Czechia, Israel, Greece, Austria
Bayer

Completed

A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults

Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Japan
Bayer

Completed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause (OASIS-3)

Hot Flashes | Vasomotor Symptoms Associated With Menopause

Belgium, United States, Poland, Spain, Bulgaria, Finland, Canada, Denmark, United Kingdom
Bayer
Nerre Therapeutics Ltd.

Completed

A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms (SWITCH-1)

Hot Flashes | Menopause | Night Waking

United States, Canada, United Kingdom
Bayer

Completed

A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years

Hot Flashes | Healthy Volunteers | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

China
Bayer

Active, not recruiting

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer (OASIS-4)

Hot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

Spain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan
Bayer

Active, not recruiting

A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women

Hot Flashes | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Canada
Bayer

Completed

A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults

Hot Flashes | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Netherlands
Bayer
Nerre Therapeutics Ltd.

Completed

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms (RELENT-1)

Post-menopausal Vasomotor Symptoms

United States
Bayer

Completed

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

Hot Flashes | Healthy Volunteers | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Germany
Bayer

Completed

A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants

Hot Flashes | Healthy Volunteers | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Germany
Bayer

Completed

A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants

Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Germany
Bayer

Recruiting

A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause (NIRVANA)

Sleep Disturbances Associated With Menopause

United States, Belgium, Austria, Czechia, Germany, Netherlands, Poland, Spain
Bayer

Completed

A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants

Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Germany
Bayer

Completed

A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.

Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Germany
University of Michigan

Completed

Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain

Periodontitis

United States
Melaka Manipal Medical College

Unknown

Clinical Evaluation of Bulk-fill vs Layered Composite Resin in Class I and II Posterior Restorations

Dental Caries Class II | Dental Caries Class I (Disorder)

Malaysia

3

Subscribe